A new generation of drugs for ATTR amyloidosis cardiomyopathy is fundamentally changing the outlook for patients whose hearts are being destroyed by misfolded protein deposits. In November 2024, the FDA approved acoramidis (brand name Attruby), an oral TTR stabilizer that demonstrated a 42% reduction in all-cause mortality and cardiovascular hospitalizations over 30 months in the ATTRibute-CM Phase 3 trial. That number climbed to a 48.2% relative risk reduction at 42 months of continuous use, making it one of the most significant advances in treating a disease that typically kills within three to five years of symptom onset.
But acoramidis is not the only breakthrough. Vutrisiran (Amvuttra), a quarterly subcutaneous injection that silences the gene responsible for producing the problematic transthyretin protein, showed a 28% lower risk of death and recurrent cardiovascular events at 36 months in the HELIOS-B trial. And further down the pipeline, a CRISPR-based gene editing therapy called nexiguran ziclumeran has produced stunning early results — a single intravenous infusion reduced the disease-causing protein by more than 90% within 28 days. This article covers the full landscape of ATTR-CM treatment in 2026: which drugs are already approved and what their trial data actually shows, what is still in clinical trials with results expected this year, how emerging gene therapies could eventually offer a one-time cure, and what all of this means for patients and caregivers navigating a diagnosis that, until recently, had almost no effective treatment options.
Table of Contents
- What New Drugs Slow Heart Damage in ATTR Amyloidosis, and How Strong Is the Trial Evidence?
- How Acoramidis Compares to Tafamidis and Why the Difference Matters
- Gene Silencing Approaches and the HELIOS-B Trial Results
- What the Ongoing CARDIO-TTRansform Trial Could Mean for Treatment in 2026
- CRISPR Gene Editing and the Promise of a One-Time Treatment
- Next-Generation siRNA Therapies in Early Development
- What These Advances Mean for Patients and Caregivers Going Forward
- Conclusion
- Frequently Asked Questions
What New Drugs Slow Heart Damage in ATTR Amyloidosis, and How Strong Is the Trial Evidence?
Three FDA-approved therapies now target ATTR cardiomyopathy through two distinct mechanisms. Tafamidis was the first approved TTR stabilizer for this indication, establishing that preventing the transthyretin protein from misfolding could meaningfully slow cardiac decline. Acoramidis, approved in November 2024, works through the same stabilization approach but with considerably stronger trial results. In the ATTRibute-CM study, benefits appeared as early as three months — the fastest onset of any Phase 3 ATTR-CM trial to date — and the drug carried no new clinically significant safety concerns through long-term follow-up. Specifically, acoramidis delivered a 44% reduction in cardiovascular mortality risk, a metric that matters enormously for a disease where the heart is the primary organ under siege. Vutrisiran takes a fundamentally different approach.
Rather than stabilizing the TTR protein after it is made, this siRNA therapy silences the transthyretin gene in the liver, reducing production of the protein altogether. The HELIOS-B trial enrolled 655 patients and found that vutrisiran not only reduced mortality and cardiovascular events but also preserved functional capacity and quality of life — outcomes that matter deeply to patients whose daily lives are constrained by heart failure symptoms like fatigue, breathlessness, and fluid retention. The distinction between these mechanisms matters clinically. Stabilizers like acoramidis and tafamidis leave the TTR protein circulating but prevent it from misfolding and depositing in the heart. Gene-silencing therapies like vutrisiran dramatically cut the amount of TTR protein the body produces in the first place. For patients and physicians, this is not just a pharmacological footnote — it shapes decisions about which drug to use, whether combinations might work, and what monitoring looks like over time.
How Acoramidis Compares to Tafamidis and Why the Difference Matters
Tafamidis was a genuine milestone when it received FDA and EMA approval for ATTR-CM, proving that pharmacological intervention could alter the course of a disease many cardiologists had considered untreatable. However, acoramidis has raised the bar. The 42% reduction in all-cause mortality and cardiovascular hospitalizations reported in ATTRibute-CM exceeded what tafamidis achieved in its pivotal trial, and the sustained benefit through 42 months of open-label follow-up suggests the drug does not lose effectiveness over time. One important caveat: direct head-to-head comparisons between acoramidis and tafamidis do not yet exist in a randomized trial setting. The ATTRibute-CM trial compared acoramidis to placebo, not to tafamidis, so claims of superiority rest on cross-trial comparisons, which carry well-known statistical limitations. Patient populations, enrollment criteria, and background therapies can all differ between studies.
That said, the magnitude of the benefit — particularly the 48.2% relative risk reduction at 42 months and the rapid three-month onset — has led many cardiologists to view acoramidis as a meaningful step forward. There is also a practical consideration. Both acoramidis and tafamidis are oral medications, which matters for an elderly patient population that may already be managing multiple prescriptions. Acoramidis is taken twice daily. If adherence is a concern — and in heart failure populations, it always should be — the dosing schedule is worth discussing with patients and caregivers. For those already stable on tafamidis, switching to acoramidis is a conversation that should involve a specialist familiar with the latest data, not an automatic decision.
Gene Silencing Approaches and the HELIOS-B Trial Results
The approval of vutrisiran for ATTR-CM represents the maturation of gene-silencing technology from a laboratory concept to a real therapeutic option. In the HELIOS-B trial, the drug was administered as a subcutaneous injection once every three months — a schedule that is substantially less burdensome than daily oral medication for some patients, particularly those with difficulty swallowing or complex pill regimens. The 28% lower risk of all-cause mortality and recurrent cardiovascular events at 36 months is clinically significant, though notably smaller in magnitude than acoramidis’s 42% reduction. Again, these figures come from different trials with different patient populations, so direct comparison requires caution. What makes vutrisiran particularly interesting is its mechanism. By using small interfering RNA to degrade the messenger RNA that encodes transthyretin, the drug attacks the problem at a genetic level rather than a protein-folding level.
For patients with hereditary ATTR amyloidosis — caused by specific mutations in the TTR gene — this approach has a logical elegance: if the mutant gene is producing a toxic protein, reducing that production should slow the disease. For wild-type ATTR, where the normal TTR protein misfolds due to aging, the rationale is the same, though the normal protein does serve some physiological functions, and the long-term implications of sustained suppression are still being studied. One limitation to keep in mind: vutrisiran requires ongoing quarterly injections indefinitely. It does not cure the disease or permanently alter the gene. If a patient stops treatment, TTR levels will rise again. This is a meaningful distinction from the gene-editing approaches now entering trials, and it is a factor in treatment planning, especially for younger patients with hereditary forms who face decades of potential therapy.
What the Ongoing CARDIO-TTRansform Trial Could Mean for Treatment in 2026
The largest ATTR-CM trial ever conducted is expected to report results in mid-2026, and its findings could reshape how clinicians approach combination therapy for this disease. The CARDIO-TTRansform Phase 3 trial enrolled more than 1,400 patients to test eplontersen (Wainua), an antisense oligonucleotide that blocks the transthyretin gene at a different stage than siRNA therapies. Eplontersen has already received FDA Fast Track designation for ATTR-CM, signaling regulatory urgency around advancing new options. What makes this trial especially relevant is that roughly 70% of enrolled patients were already taking tafamidis. This design directly tests whether adding eplontersen to an existing stabilizer provides additional benefit — a combination strategy that reflects real-world clinical practice, where physicians are reluctant to abandon a therapy that is partially working.
Earlier data from eplontersen studies showed stable or improved cardiac structure and function compared to historical placebo controls in patients with hereditary ATTR, but the CARDIO-TTRansform results will provide the definitive answer on additive benefit. The tradeoff with combination therapy is always complexity and cost. If eplontersen proves beneficial on top of tafamidis, patients could be looking at a daily oral pill plus a regular injection, along with the cumulative side effect profiles of both. Payers and health systems will also grapple with the economics of stacking specialty-priced therapies. For patients, though, the calculus may be simpler: ATTR-CM is fatal, and any additional slowing of cardiac damage is worth pursuing if the side effects are tolerable.
CRISPR Gene Editing and the Promise of a One-Time Treatment
Perhaps the most striking development in the ATTR amyloidosis pipeline is nexiguran ziclumeran, known as nex-z, developed by Intellia Therapeutics. This is the first in vivo CRISPR/Cas9 gene editing therapy for ATTR amyloidosis, and its early data is remarkable: a single intravenous infusion reduced serum TTR levels by more than 90% within 28 days, with 92–94% reductions sustained through four to six months. In the Phase 1 study of 12 participants, the therapy was generally well-tolerated, though one serious adverse event was reported and subsequently resolved. The MAGNITUDE Phase 3 trial is now underway, randomizing approximately 765 patients to receive either a single 55 mg intravenous infusion of nex-z or placebo, with follow-up extending 18 to 48 months. Phase 3 completion is estimated for 2028. If the results hold, nex-z would represent something fundamentally different from every other therapy discussed here: a one-time treatment that permanently edits the TTR gene, potentially eliminating the need for lifelong medication.
The caveats are significant, however. CRISPR gene editing in living humans is still new territory, and long-term safety data simply does not exist yet. Off-target edits — where the CRISPR machinery cuts DNA in unintended locations — remain a theoretical concern despite not appearing in early data. The irreversibility of gene editing is both its greatest strength and its greatest risk. Unlike a stabilizer or siRNA therapy that can be stopped if problems arise, a permanent genetic change cannot be undone. Patients and physicians will need to weigh transformative potential against genuine uncertainty, and the 2028 timeline means this decision point is still years away for most people.
Next-Generation siRNA Therapies in Early Development
Beyond the currently approved and late-stage options, Alnylam Pharmaceuticals is developing nucresiran (ALN-TTRsc04), a next-generation siRNA that may offer improvements over vutrisiran in potency and dosing convenience. Phase 1 results showed that a single subcutaneous dose reduced serum TTR levels by more than 90% at 15 days and 96% by 29 days, with suppression sustained for six months. If these results translate into later-stage trials, nucresiran could potentially be dosed just twice a year — a meaningful improvement for patients managing a chronic, lifelong condition. This matters in context because treatment burden is a real factor in cardiac amyloidosis care.
Many patients are elderly, often dealing with concurrent conditions like atrial fibrillation, kidney disease, or neuropathy. Every reduction in injection frequency or clinic visit represents a tangible improvement in quality of life. Still, nucresiran is in early development, and the gap between impressive Phase 1 pharmacodynamics and proven clinical outcomes in Phase 3 is wide. Many promising drugs have faltered at that stage.
What These Advances Mean for Patients and Caregivers Going Forward
The treatment landscape for ATTR amyloidosis cardiomyopathy has changed more in the past two years than in the preceding two decades. Patients diagnosed today have access to at least three FDA-approved therapies, with trial data supporting meaningful reductions in mortality and hospitalizations. The question is no longer whether effective treatment exists but rather which therapy — or combination of therapies — is best for a given patient’s disease subtype, stage, and overall health profile.
For caregivers of people with dementia-related conditions who may also be dealing with cardiac amyloidosis, these advances carry a particular significance. ATTR amyloidosis can co-occur with cognitive decline, especially in older adults with wild-type disease, and its cardiac symptoms — fatigue, shortness of breath, swelling — can complicate dementia care and reduce quality of life for both patients and their families. The availability of treatments that reduce hospitalizations and preserve functional capacity may help keep patients at home and more engaged in daily life for longer. As the CARDIO-TTRansform and MAGNITUDE trials report results over the coming years, the options will only expand — and with them, the realistic hope that this once-untreatable disease can be meaningfully managed.
Conclusion
ATTR amyloidosis cardiomyopathy is no longer the therapeutic dead end it was even five years ago. Acoramidis has set a new benchmark with its 48.2% relative risk reduction in mortality and cardiovascular hospitalizations at 42 months, vutrisiran offers a gene-silencing alternative with quarterly dosing, and tafamidis remains an established option. The CARDIO-TTRansform trial results expected in mid-2026 could add eplontersen to the toolkit, potentially as part of combination regimens, while the MAGNITUDE trial of CRISPR-based nex-z may ultimately offer a one-time curative approach by 2028.
For patients and caregivers, the most important step is early and accurate diagnosis — none of these therapies can help if the disease is not identified. Anyone experiencing unexplained heart failure symptoms, especially after age 60, should ask their cardiologist about ATTR amyloidosis screening. The treatments are here, and they are getting better rapidly. The challenge now is ensuring that the people who need them actually receive them in time.
Frequently Asked Questions
What is ATTR amyloidosis cardiomyopathy?
ATTR-CM is a progressive, fatal condition where the transthyretin protein misfolds and deposits in the heart muscle, leading to heart failure. It occurs in two forms: hereditary, caused by genetic mutations in the TTR gene, and wild-type, associated with aging. Without treatment, most patients die within three to five years of symptom onset.
What is the most effective approved drug for ATTR-CM right now?
Based on available trial data, acoramidis (Attruby) showed the strongest results among approved therapies, with a 42% reduction in mortality and cardiovascular hospitalizations at 30 months in the ATTRibute-CM trial. However, no head-to-head trials comparing it directly to tafamidis or vutrisiran have been published, so “most effective” depends partly on the individual patient’s situation and disease subtype.
Can ATTR amyloidosis affect the brain or cause dementia?
ATTR amyloidosis primarily affects the heart and peripheral nerves, but it frequently occurs in older adults who may also have age-related cognitive decline or dementia from other causes. The hereditary form can cause peripheral neuropathy, and the cardiac symptoms of ATTR-CM — fatigue, reduced exercise tolerance, and fluid overload — can worsen cognitive function and complicate dementia care.
Is there a cure for ATTR amyloidosis?
No approved cure exists yet. Current treatments slow disease progression by stabilizing the TTR protein or reducing its production. The CRISPR gene editing therapy nex-z is the closest candidate for a potential cure, as it permanently edits the TTR gene with a single infusion, but it remains in Phase 3 trials with completion expected in 2028.
How is ATTR-CM diagnosed?
Diagnosis typically involves a combination of cardiac imaging, nuclear scintigraphy (a specific bone tracer scan that can detect TTR deposits in the heart without a biopsy in many cases), and genetic testing to distinguish hereditary from wild-type forms. The disease is widely underdiagnosed because its symptoms overlap with more common causes of heart failure.
Are these new drugs covered by insurance?
Coverage varies by payer and country. Tafamidis, the longest-approved option, has the broadest coverage but is expensive, with list prices exceeding $200,000 per year in the United States. Acoramidis and vutrisiran face similar pricing challenges. Patient assistance programs exist through most manufacturers, and specialty pharmacies can help navigate access.
